Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
Trial ID or NCT#
The purpose of this study is to compare the Overall Survival (OS) of HCC patients who receive brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive matched placebo with TACE therapy.
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)
Contact us to find out if this trial is right for you.
Cancer Clinical Trials Office
View on ClinicalTrials.gov